Does UnitedHealthcare Cover Vyvanse? Formulary Tier, Prior Authorization, and Appeal Steps

Vyvanse is the brand name for lisdexamfetamine dimesylate, a prodrug that is metabolized to dextroamphetamine after ingestion. It is distinct from other stimulants such as methylphenidate (Ritalin, Concerta) and from immediate-release amphetamine salts (Adderall), and insurers typically treat it as its own formulary line rather than grouping it with those drugs for tiering purposes.

The core answer, with its boundary

UnitedHealthcare commercial plans cover Vyvanse for its FDA-approved indications, subject to prior authorization and, on many plans, step therapy through a generic stimulant. This is a general pattern across commercial pharmacy benefit design, not a guarantee for any individual plan: tier placement, exact copay amounts, and whether step therapy applies at all differ by employer group, plan year, and state. The only way to know your specific terms is to check your plan's current formulary and clinical policy through MyUHC.com or the number on your member ID card, because UnitedHealthcare renews formulary and utilization-management decisions annually.

Formulary placement: what usually happens, and why it shifts

Historically, brand-name Vyvanse sat on Tier 3 (non-preferred brand) on many UnitedHealthcare commercial formularies, meaning a higher cost-share than Tier 1 or Tier 2 generics. Since the authorized generic of lisdexamfetamine launched in August 2023, some UnitedHealthcare formularies have moved brand Vyvanse further down the preference order while placing the authorized generic at a lower generic tier. Whether your plan has made that shift, and what the resulting copay difference actually is, requires checking your current formulary rather than assuming last year's tier still applies.

If your pharmacy fills brand Vyvanse but your plan's formulary lists the authorized generic at a lower tier, asking your prescriber and pharmacist about a generic substitution is a reasonable first step before pursuing a tier exception.

Prior authorization: what the process generally requires

UnitedHealthcare requires prior authorization for Vyvanse on nearly all commercial plan designs. In general, PA criteria for stimulant medications require documentation that the prescribed use matches an FDA-approved indication and that appropriate clinical criteria are met before the plan pays.

ADHD coverage typically requires a formal DSM-5 diagnosis and, when step therapy applies, evidence that the patient has not responded adequately to or cannot tolerate at least one first-line generic stimulant. According to its FDA label, Vyvanse is approved for treating ADHD in patients 6 years of age and older, as well as for moderate-to-severe binge eating disorder in adults (approval for the latter indication was added in January 2015). The FDA label serves as the authoritative regulatory document defining Vyvanse's approved uses (FDA label, accessdata.fda.gov).

For binge eating disorder, PA criteria typically require a confirmed BED diagnosis and documentation that behavioral interventions alone have not achieved adequate control. Prescribers are generally also asked to confirm the medication is not being used for weight loss, since weight management is an off-label use for Vyvanse and is not a covered indication under standard formulary criteria.

A note on prior clinical-trial citations: earlier drafts of this page cited specific randomized-trial identifiers for ADHD and BED efficacy. Those identifiers could not be independently verified against the papers they were attributed to, so they have been removed rather than left in place with the wrong paper attached. The underlying clinical point, that lisdexamfetamine has trial evidence supporting efficacy in both ADHD and BED, is supported by the FDA-approved label itself; a reader who wants the specific pivotal trials should look them up directly in the label's clinical studies section or in a database such as ClinicalTrials.gov rather than relying on a citation carried over from an earlier version of this page.

PA submissions generally go through CoverMyMeds, the UnitedHealthcare provider portal, or fax. Standard PA decisions are commonly reported to take about 48 to 72 hours, with expedited review available when a prescriber attests that a standard timeline could seriously jeopardize the patient's health. These timeframes are typical, not contractual guarantees, and can vary by plan.

Step therapy: when it applies and when it can be skipped

Many UnitedHealthcare plans require a documented trial of a generic stimulant, commonly generic mixed amphetamine salts or generic methylphenidate, before authorizing Vyvanse for ADHD. A trial is usually considered adequate at around 30 days at an appropriate dose, though this varies by plan's clinical policy.

A step is generally considered "failed" when the patient had inadequate symptom control at an appropriate dose, intolerable side effects, or a documented contraindication. Vague chart notes ("patient failed generics") without a named drug, dose, and outcome are a common reason PA submissions get denied and have to be resubmitted.

Patients moving from a plan that already covered Vyvanse may be able to use a continuity-of-care provision to continue their current medication for a limited window while new plan requirements are satisfied. Not every employer-sponsored UnitedHealthcare plan uses step therapy at all; benefit design is set at the employer group level, which is one more reason plan-level verification matters more than general expectations.

Step therapy generally does not apply to the binge eating disorder indication, because Vyvanse is the only FDA-approved pharmacotherapy specifically for moderate-to-severe BED and there is no generic alternative carrying that indication.

Appealing a denial

UnitedHealthcare's appeal structure generally follows this pattern: an internal appeal (or two levels of internal appeal, depending on plan type), followed by external review through an independent review organization (IRO) if internal appeals are unsuccessful. The IRO's decision is binding on the plan. General information about external review rights is available through CMS (cms.gov), though CMS does not publish a single national statistic on prescription-drug overturn rates that applies uniformly across payers and drug classes; a reader who wants a specific overturn-rate figure should look for state-level external review data, since that oversight is largely administered at the state insurance department level for commercial plans.

For a step-therapy-based denial, the strongest appeals generally include clinical documentation naming the specific first-step medication tried, the dose, the duration, and the specific adverse effect or lack of response observed, ideally supported by an objective measure such as a validated ADHD rating scale.

A peer-to-peer conversation between the prescribing clinician and a UnitedHealthcare medical director is available at most stages of review and often resolves a denial faster than a written appeal alone.

Cost-saving options worth checking

Authorized generic lisdexamfetamine. Available since August 2023, this is the same medication as brand Vyvanse manufactured under the brand license, and it may sit at a lower formulary tier depending on your plan. Ask your prescriber or pharmacist whether substitution is possible.

Manufacturer savings card. Takeda's Vyvanse savings program can reduce out-of-pocket costs for commercially insured patients; it cannot be used with Medicare, Medicaid, or Tricare. Check the manufacturer's current program terms directly, since caps and eligibility rules change over time and are not something this article can state precisely as of a fixed date.

Mail-order pharmacy. UnitedHealthcare's OptumRx mail-order benefit often prices a 90-day supply below three separate 30-day copays for maintenance medications, though the exact discount depends on your plan design.

Tier exception request. If your plan places the authorized generic (or brand Vyvanse) at a higher tier than you believe is warranted, a prescriber can submit a formal tier exception request, typically strongest when supported by documentation of a specific clinical need or a cost-related adherence problem.

Generic availability information, including which manufacturers have FDA-approved generic or authorized-generic lisdexamfetamine products, is tracked in the FDA Orange Book (fda.gov).

Coverage by population

Pediatric patients (ages 6 to 17). Coverage generally follows the same PA and, where applicable, step-therapy framework as adult ADHD coverage. Clinical guidelines from bodies such as the American Academy of Pediatrics support stimulant medication as a first-line pharmacologic option for ADHD in this age group; a reader who needs to cite the specific guideline document for a PA submission should pull the current AAP clinical practice guideline directly rather than relying on a secondhand citation.

Adults with binge eating disorder. Because Vyvanse is the only FDA-approved medication specifically indicated for moderate-to-severe BED, step therapy through other stimulants generally does not apply to this indication. PA still typically requires confirmation that the prescriber is treating BED specifically and not using the drug off-label for weight loss.

Medicare Advantage (including UnitedHealthcare/AARP plans). Part D formularies often place Vyvanse at a higher, non-preferred tier than commercial formularies, with correspondingly higher cost-sharing. The manufacturer savings card cannot be used with Medicare; patients on a fixed income should ask about Extra Help (the Part D Low-Income Subsidy) or state pharmaceutical assistance programs instead.

Student health plans. UnitedHealthcare Student Resources plans generally follow a similar commercial formulary structure, so students newly diagnosed with ADHD should expect the standard PA process and possibly step therapy.

What actually changes what you should do

Vyvanse coverage decision path (UnitedHealthcare commercial plans)

This table reflects general UnitedHealthcare utilization-management patterns for CNS stimulants, not a guarantee of outcome for any specific plan or patient. Clinical policy bulletins and formulary files are the authoritative source for your plan and should be checked directly.

What is established, what is plausible, and what is not established

Established: Vyvanse is FDA-approved for ADHD in patients 6 and older and for moderate-to-severe binge eating disorder in adults, per the current FDA label. UnitedHealthcare commercial plans generally require prior authorization for Vyvanse, and many also apply step therapy for the ADHD indication specifically.

Plausible but plan-dependent: Exact formulary tier, copay amount, PA turnaround time, and whether step therapy is enforced at all vary by specific employer plan and change at each formulary renewal. General ranges reported for these figures are not something this article can state as fixed facts for your plan.

Not established from the sources available here: A specific national percentage of external reviews overturned for stimulant medications, a specific prescription-volume figure for lisdexamfetamine, and the specific pivotal trial citations for ADHD and BED efficacy that appeared in earlier versions of consumer-facing coverage pages. Readers who need these for a formal appeal packet should pull them from the FDA label, ClinicalTrials.gov, or their state insurance department's external review data directly.